With the UK’s default to leave the EU without a deal, there are a number of steps businesses in the life sciences sector should take to prepare. Many companies in the sector are faced with simultaneously navigating an increasingly complex regulatory environment while trying to mitigate as much as possible the significant impact of Brexit – including the effects of weak drug development pipelines, access to talent, supply chain disruption and potentially reduced research and development (R&D) funding.
Only logged in customers who have purchased this product may leave a review.
You may also like
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry. Each of the major pharma players is investing in the technology at some level, and there are a growing number of applications that address target and drug discovery, preclinical and clinical development, and postapproval activities.
Artificial Intelligence in Life Sciences$0.00 LEK
SUPPLY chains traditionally are linear in nature, with a discrete progression of design, plan, source, make, and deliver. Today, however, many supply chains are transforming from a staid sequence to a dynamic, interconnected system that can more readily incorporate ecosystem partners and evolve to a more optimal state over time.
The rise of the digital supply network$0.00 Deloitte
On display in the Berlin Air Show in June 2016 was ‘Thor’ – the small Airbus marvel that is the world’s first aircraft wholly produced by additive manufacturing (AM). Windowless weighing in at just 21 kilos (46 pounds) and less than four meters (13 feet) long, the drone Thor – short for “Test of High-tech Objectives in Reality” – resembles a large, white model airplane.
3D Printing$0.00 Ipsos Business consulting
Trouble with Conavigo
Want to refine your results?
Help with Sourcing
Need help with your Sourcing?